Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
How Dermatologists Can Ethically and Strategically Interact with Industry
Description
The speaker explains how dermatologists can interact with industry in ethical, strategic, and professional ways while maintaining patient trust and personal integrity. They outline common paths of engagement, including working with medical science liaisons, thought leader liaisons, advisory boards, investigator-initiated studies, clinical trials, speaker bureaus, and even industry medical-director roles. Key terms such as KOL, MSL, TLL, and advisory board are defined, with emphasis that these relationships should be based on expertise and professionalism rather than quid pro quo or pressure to prescribe. The talk stresses being nice, following compliance rules, staying on-label, avoiding inappropriate requests or favoritism, and always doing independent research. Rep interactions should be businesslike, respectful, and educational, not personal or transactional. The speaker also highlights the value of staying clinically active, developing a niche, publishing, lecturing, and building a visible CV to become a true thought leader rather than merely a slide reader. Additional practical points include the Sunshine Act, transparency in disclosures, payment structures, and the importance of attending major dermatology meetings like AAD and Fall Clinical to stay current and build networks. Overall, the message is to engage with industry thoughtfully, preserve street cred, and use these relationships to improve dermatologic care and advance one’s career without compromising ethics.
View moreConclusions
- Meaningful interaction with industry is presented as a normal and potentially valuable part of dermatology when handled ethically and professionally.
- Physicians should choose the industry roles that fit their interests and expertise, such as investigator, advisor, speaker, or medical director, rather than pursuing titles for status alone.
- Medical science liaisons and thought leader liaisons are portrayed as useful resources for clinical information, trial access, and career strategy, especially for staying current with emerging data.
- Sales representatives are described as educational contacts rather than personal conveniences, and the relationship should remain respectful, businesslike, and bound by clear boundaries.
- Off-label questions and scientific nuance should be handled through appropriate medical channels, not through sales reps, to avoid compliance problems.
- Advisory boards are framed as a legitimate way to earn compensation for informed opinion, with honest dissent and tactful engagement valued over yes-man behavior.
- Speaker bureau participation should be based on genuine expertise and compliance, with the emphasis on educating within label and not using prescribing volume as a basis for selection.
- Transparency about payments and disclosures is important, but the speaker argues that it does not by itself invalidate a physician’s credibility if the relationship remains open and compliant.
- Maintaining clinical practice and real patient care is presented as essential for preserving relevance, street credibility, and practical judgment.
- The best way to build a durable industry-facing career is to be knowledgeable, ethical, selective, and respectful while continuing to contribute through clinical work, research, and education.
- https://openpaymentsdata.cms.gov/